Personalis

PSNL Small Cap

Healthcare · Diagnostics & Research

Updated: Apr 5, 2026, 17:43 UTC

$6.58

+0.3% today

52W: $2.83 – $11.50

52W Low: $2.83 Position: 43.3% 52W High: $11.50

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

9.89x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$688.5M

Market Capitalization

Revenue Growth

3.2%

YoY Revenue Growth

Profit Margin

-116.69%

Net profit margin

ROE

-35.02%

Return on Equity

Beta

2.21

Market sensitivity

Short Interest

14.44%

% of float sold short

Avg. Volume

1,469,921

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

7 analysts

Avg. Price Target

$11.43

+73.69% upside

Target Range

$10.00 – $13.00

About the Company

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In ad

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 259 Exchange: NGM